Compare QTTB & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | INVE |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.5M | 115.7M |
| IPO Year | 2018 | 1997 |
| Metric | QTTB | INVE |
|---|---|---|
| Price | $11.98 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.00 | $5.50 |
| AVG Volume (30 Days) | ★ 1.4M | 73.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $53,737,000.00 | ★ $60,219,000.00 |
| Revenue This Year | N/A | $22.10 |
| Revenue Next Year | N/A | $20.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.21 |
| 52 Week Low | $1.40 | $3.08 |
| 52 Week High | $14.85 | $5.30 |
| Indicator | QTTB | INVE |
|---|---|---|
| Relative Strength Index (RSI) | 57.73 | 47.34 |
| Support Level | $2.93 | $3.14 |
| Resistance Level | $14.85 | $4.07 |
| Average True Range (ATR) | 1.56 | 0.17 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 27.43 | 33.42 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.